This is a phase I/II study of the combination of cyclophosphamide, BCNU, and etoposide in the treatment of refractory lymphoma. The phase I aspect is complete and the acceptable dose is cyclophosphamide 7.2g/m2, BCNU 450mg/m2, and etoposide 1800mg/m2. We are now in the phase II part of the trial and are assessing efficacy as measured by freedom from progression of lymphoma.
Showing the most recent 10 out of 721 publications